Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.94 +3.5%	$16.16	$9.57 ▼ $29.86	$2.61B	0.93	1.57 million shs	598,940 shs
MIRM Mirum Pharmaceuticals	$52.79 0.0%	$48.00	$36.20 ▼ $55.05	$2.61B	0.97	453,829 shs	154,875 shs
OGN Organon & Co.	$9.64 +0.1%	$9.50	$8.01 ▼ $23.10	$2.50B	0.6	3.59 million shs	1.51 million shs
ZVRA Zevra Therapeutics	$12.68 +2.9%	$9.36	$5.45 ▼ $13.16	$691.98M	1.97	731,119 shs	867,636 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.80%	-3.07%	+16.56%	+62.81%	-38.05%
MIRM Mirum Pharmaceuticals	+1.58%	-1.23%	+4.72%	+35.04%	+32.00%
OGN Organon & Co.	+0.63%	-3.26%	-5.57%	-13.26%	-53.70%
ZVRA Zevra Therapeutics	-3.67%	+6.57%	+34.94%	+72.31%	+88.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7556 of 5 stars	3.4	2.0	0.0	3.4	3.1	1.7	0.0
MIRM Mirum Pharmaceuticals	3.0978 of 5 stars	2.6	0.0	0.0	4.2	2.5	1.7	0.6
OGN Organon & Co.	4.8248 of 5 stars	3.3	3.0	1.7	3.7	1.8	3.3	2.5
ZVRA Zevra Therapeutics	3.0895 of 5 stars	3.6	5.0	0.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	130.80% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	24.09% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	86.82% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	87.02% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, MIRM, OGN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	4.80	N/A	N/A	$1.54 per share	12.30
MIRM Mirum Pharmaceuticals	$336.89M	7.76	N/A	N/A	$4.70 per share	11.23
OGN Organon & Co.	$6.29B	0.40	$4.97 per share	1.94	$1.83 per share	5.27
ZVRA Zevra Therapeutics	$40.59M	17.08	N/A	N/A	$0.74 per share	17.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	20.73	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.35	2.58	0.99	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	63.40	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest ZVRA, MIRM, OGN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.83%	N/A	2.78%	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest ZVRA, MIRM, OGN, and ARWR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
OGN Organon & Co.	16.49	1.67	1.15
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
MIRM Mirum Pharmaceuticals	N/A
OGN Organon & Co.	77.43%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
MIRM Mirum Pharmaceuticals	14.36%
OGN Organon & Co.	1.96%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

ZVRA, MIRM, OGN, and ARWR Headlines

Recent News About These Companies

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.

5 hours ago | marketbeat.com

William Blair Issues Optimistic Forecast for ZVRA Earnings

July 17 at 2:25 AM | americanbankingnews.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...

July 16 at 4:53 PM | finanznachrichten.de

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

July 16 at 1:01 PM | zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16 at 10:05 AM | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 16 at 8:13 AM | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

July 16 at 7:52 AM | quiverquant.comQ

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?

July 16 at 6:20 AM | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

July 16 at 6:02 AM | marketbeat.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 12:40 PM | finance.yahoo.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 10:56 AM | zacks.com

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)

July 15 at 9:50 AM | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Brokerages

July 15 at 2:03 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from Analysts

July 15 at 2:29 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street Zen

July 14 at 2:23 AM | americanbankingnews.com

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings

July 14 at 2:40 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

July 13, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

July 11, 2025 | finance.yahoo.com

Zevra Therapeutics Showcases MIPLYFFA® Data at National Niemann Pick Disease Foundation Conference

July 11, 2025 | quiverquant.comQ

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Stratos Wealth Partners LTD.

July 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop

ZVRA, MIRM, OGN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.94 +0.64 (+3.50%)

As of 02:32 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$52.78 -0.02 (-0.03%)

As of 02:32 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organon & Co. NYSE:OGN

$9.64 +0.01 (+0.05%)

As of 02:32 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Zevra Therapeutics NASDAQ:ZVRA

$12.68 +0.36 (+2.92%)

As of 02:32 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time